Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
European Urology|June 27, 2021
Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic ReviewRicardo Leão, Maarten Albersen, Leendert H J Looijenga, et al.
Frontiers in Oncology|August 15, 2022
Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic StudiesLeonard Lugand, Guillaume Mestrallet, Rebecca Laboureur, et al.
Cancer Immunology Research|August 28, 2019
CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-GClement Dumont, Alix Jacquier, Jerome Verine, et al.
Future Oncology (London, England)|February 20, 2025
Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in FranceFlorence Joly, Stephane Culine, Morgan Roupret, et al.
Urology|May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, Christophe Massard, Mitchell E Gross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, George Wilding, Edwin Posadas, et al.
European Urology|October 8, 2013
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective studyKarim Fizazi, Rémi Delva, Armelle Caty, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
Oncotarget|September 22, 2018
Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cellsFrancois Desgrandchamps, Joel LeMaoult, Annabelle Goujon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
Pageof 4